NCT03277469 is a NA clinical trial of MRI in Gynecologic Cancer, sponsored by Dana-Farber Cancer Institute.

Who is sponsoring NCT03277469?

NCT03277469 is sponsored by Dana-Farber Cancer Institute.

What drugs are being tested in NCT03277469?

Interventions in NCT03277469: MRI, Brachytherapy, MRI Tracker.

What condition does NCT03277469 study?

NCT03277469 studies Gynecologic Cancer.

Is NCT03277469 still recruiting?

NCT03277469 is currently active, enrolled. Last updated 31 October 2024.

Last reviewed 2024-10-31 · How we verify

NCT03277469

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Optimizing Brachytherapy Application and Delivery With MRI Guidance for Gynecologic Cancer

Active, enrolled NA Last updated 31 October 2024

What this trial tests

NA trial testing MRI in Gynecologic Cancer in 49 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

13 November 2017

Primary endpoint
15 September 2025

15 September 2027

Quick facts

Lead sponsor	Dana-Farber Cancer Institute
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	49
Start date	13 November 2017
Primary completion	15 September 2025
Estimated completion	15 September 2027
Sites	1 location across United States

Drugs / interventions tested

MRI — full drug profile →
Brachytherapy — full drug profile →
MRI Tracker

Conditions studied

Gynecologic Cancer — all drugs for Gynecologic Cancer →

Sponsor

Dana-Farber Cancer Institute

Who can join

18 and older, female only, with Gynecologic Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to develop new tools using magnetic resonance imaging (MRI) that will improve the brachytherapy procedure and treatment for participants with gynecologic cancer.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Review of brachytherapy clinical trials: a cross-sectional analysis of ClinicalTrials.gov.
Chen D, Parsa R, Chauhan K, Lukovic J, et al · · 2024 · cited 2× · PMID 38351013 · DOI 10.1186/s13014-024-02415-8

Verify or expand the search:

Other trials of MRI

Trials testing the same drug.

NCT02831335 — Technical Development of Multi-Parametric Renocerebral MRI · recruiting
NCT07487870 — Radiographic Evaluation of Tumor Biology During Neoadjuvant Radiotherapy for Sarcoma · NA · not yet recruiting
NCT07567053 — Repetitive Transcranial Magnetic Stimulation on Motor Function and Meta-Plasticity in Cerebral Palsy: TMS-EEG Study · NA · not yet recruiting
NCT07537504 — Language Function Reorganization in Patients With Arteriovenous Malformations · not yet recruiting
NCT07217990 — Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer · Phase 1, PHASE2 · not yet recruiting

Other recruiting trials for Gynecologic Cancer

Currently open trials in the same condition.

NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07408349 — Guided Imagery of the Gynecological Cancer · NA · recruiting
NCT07447050 — Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial · Phase 2 · recruiting
NCT07173101 — Clinical Investigation of the Effects of Semiconductor Embedded Therapeutic Garments on Cancer-related Cognitive Impairm · Phase 2 · recruiting
NCT07166042 — Guided Meditation During Radiation Therapy for Breast and Gynecological Malignancies · Phase 3 · recruiting

Other Dana-Farber Cancer Institute trials

Trials by the same sponsor.

NCT07519200 — Sexual Health and Rehabilitation for Women With Metastatic Breast Cancer (SHARE-MC): An Educational Intervention · NA · not yet recruiting
NCT07499999 — Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk fo · Phase 2 · not yet recruiting
NCT05825469 — Development and Testing of Nutritional Algorithms (NACHO) · NA · not yet recruiting
NCT07516353 — my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults · NA · not yet recruiting
NCT07513324 — Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0) · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03277469 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dana-Farber Cancer Institute
Last refreshed: 31 October 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03277469.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing